TORL BioTherapeutics LLC, a clinical stage biotechnology company discovering and developing new antibody-based immunotherapies to improve and extend the lives of patients with cancer worldwide, announced closing of a $96 million Series C financing. Additionally, updated results from the ongoing Phase 1 study of the Company's Claudin 6 (CLDN6) targeted antibody-drug conjugate (ADC) TORL-1-23 in patients with advanced cancer will be presented in poster sessions at the 2025 European Society of Medical Oncology Congress (ESMO 2025) in Berlin, Germany.